James Warburton

1.3k total citations · 1 hit paper
8 papers, 950 citations indexed

About

James Warburton is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, James Warburton has authored 8 papers receiving a total of 950 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Ophthalmology, 4 papers in Radiology, Nuclear Medicine and Imaging and 1 paper in Surgery. Recurrent topics in James Warburton's work include Retinal Diseases and Treatments (5 papers), Retinal Imaging and Analysis (4 papers) and Retinal and Optic Conditions (3 papers). James Warburton is often cited by papers focused on Retinal Diseases and Treatments (5 papers), Retinal Imaging and Analysis (4 papers) and Retinal and Optic Conditions (3 papers). James Warburton collaborates with scholars based in Switzerland, United Kingdom and United States. James Warburton's co-authors include Andreas Weichselberger, Pravin U. Dugel, Glenn J. Jaffe, Ursula Schmidt‐Erfurth, Yuichiro Ogura, David M. Brown, Adrian Koh, André Vieira Gomes, Frank G. Holz and Peter Sallstig and has published in prestigious journals such as Ophthalmology and Ecological Indicators.

In The Last Decade

James Warburton

7 papers receiving 926 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

2019 623 citations Pravin U. Dugel, Adrian Koh et al. Ophthalmology profile →

Peers

James Warburton

OPHTH

RNMI

MB

IMMUN

RHEUM

Prema Abraham United States

Yehia Hashad United States

Johannes P. H. van de Ven Netherlands

Sara Brandi Bloch Denmark

Jun Ling China

Sofia Fonseca Portugal

Nour Maya N. Haddad United States

Mingzhen Yuan China

Gabriella Widmer Switzerland

Petri Mäkinen Finland

Prema Abraham United States

James Warburton

1.8k ×2.0

OPHTH

1.5k ×2.2

RNMI

210 ×1.3

MB

29 ×0.6

IMMUN

17 ×0.7

RHEUM

Citations per year, relative to James Warburton James Warburton (= 1×) peers Prema Abraham

Countries citing papers authored by James Warburton

Since Specialization

Citations

This map shows the geographic impact of James Warburton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Warburton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Warburton more than expected).

Fields of papers citing papers by James Warburton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Warburton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Warburton. The network helps show where James Warburton may publish in the future.

Co-authorship network of co-authors of James Warburton

This figure shows the co-authorship network connecting the top 25 collaborators of James Warburton. A scholar is included among the top collaborators of James Warburton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Warburton. James Warburton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Ding, Helen, et al.. (2023). Tackling the challenges of assessing socioeconomic impacts of farmland restoration: The case of Malawi. Ecological Indicators. 148. 110068–110068. 2 indexed citations

2.

Dugel, Pravin U., Adrian Koh, Yuichiro Ogura, et al.. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 127(1). 72–84. 623 indexed citations breakdown →

3.

Dugel, Pravin U., Glenn J. Jaffe, Peter Sallstig, et al.. (2017). Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology. 124(9). 1296–1304. 179 indexed citations

4.

Dugel, Pravin U., James Warburton, Andreas Weichselberger, & Peter Sallstig. (2016). A 2-year study comparing the efficacy and safety of brolucizumab vs aflibercept in subjects with neovascular age-related macular degeneration: testing an alternative treatment regimen. 57(12). 5018–5018. 4 indexed citations

5.

Pető, Tünde, et al.. (2016). Grading OCT characteristics did not clearly predict treatment outcomes in the RELIGHT study participants. 57(12). 2084–2084.

6.

Waldstein, Sebastian M., Victor Chong, Michael Larsen, et al.. (2016). Association of fluid recurrence with visual maintenance following the loading phase in anti-VEGF therapy for neovascular AMD. 57(12). 533–533. 2 indexed citations

7.

Pearce, Ian, Sanjiv Banerjee, Ben Burton, et al.. (2015). Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment. Ophthalmology. 122(9). 1811–1819. 37 indexed citations

8.

Waldstein, Sebastian M., Jonathan Wright, James Warburton, et al.. (2015). Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. Ophthalmology. 123(1). 60–69. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact